Baldwin AG, Rivers-Auty J, Daniels MJ, White CS, Schwalbe CH, Schilling T, Hammadi H, Jaiyong P, Spencer NG, England H, Luheshi NM, Kadirvel M, Lawrence CB, Rothwell NJ, Harte MK, Bryce RA, Allan SM, Eder C, Freeman S, Brough D. Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell Chem Biol. 2017 Nov 16;24(11):1321-1335.e5. Epub 2017 Sep 21 PubMed.
Recommends
Please login to recommend the paper.
Comments
The Walter and Eliza Hall Institute
I don’t know how bioavailable the boron compounds will be in the CNS, but the safety profile associated with targeting NLRP3 should be quite good. There are currently five companies that have been formed to make NLRP3 inhibitors, in the hope of getting them into the clinic, although perhaps Alzheimer’s is not the first indication they will target.
View all comments by Seth MastersMake a Comment
To make a comment you must login or register.